Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his tenure, Bayer has returned to growth, brought the global innovation portfolio to Portuguese patients and healthcare professionals in areas such as cardiology, ophthalmology, oncology, hemophilia and contraception.
What milestones have you reached over the past three years of being country manager for Portugal?
"The Portuguese are innovative and given that we have limited resources, we are often more creative and innovative than other countries. This allows us to experiment with new approaches that we can then replicate in other markets."
